NICE guidance on rituximab for first-line treatment of symptomatic stage III–IV follicular lymphoma in previously untreated patients

Doss, Sally; Garrett, Zoe; Sutcliffe, Frances; Stevens, Andrew

doi:10.1016/s1470-2045(12)70009-8

Cited by 4 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, rituximab faced no major social or political barriers in its initial or subsequent approval processes in the United States. Rituximab has also been approved by the European Commission and is currently recommended by the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom as first‐line treatment for FL . Additionally, NICE has recommended rituximab for the treatment of RA after the failure of tumor necrosis factor antagonists .…”

Section: Social and Political Influences On Translationmentioning

confidence: 99%

Rituximab for Non‐Hodgkin's Lymphoma: A Story of Rapid Success in Translation

Harrison

Thalji

Greenberg

et al. 2013

Clinical Translational Sci

View full text Add to dashboard Cite

Translational stories range from straightforward to complex. In this commentary, the story of the rapid and successful translation of rituximab therapy for the treatment of non-Hodgkin’s lymphoma (NHL) is examined. Development of this monoclonal antibody therapy began in the late 1980s. In 1994, rituximab received its first approval for the treatment of NHL by the United States Food and Drug Administration (FDA). Rituximab has since been approved for additional indications and has transformed medical practice. However, the social and political implications of these rapid successes are only beginning to become clear. In this commentary, key events in the rapid translation of rituximab from the bench to bedside are highlighted and placed into this historical framework. To accomplish this, the story of rituximab is divided into the following six topics, which we believe to be widely applicable to case studies of translation: (1) underlying disease, (2) key basic science, (3) key clinical studies in translation, (4) FDA approval process, (5) changes to medical practice, and (6) the social and political influences on translation.

show abstract

Section: Social and Political Influences On Translationmentioning

confidence: 99%

Rituximab for Non‐Hodgkin's Lymphoma: A Story of Rapid Success in Translation

Harrison

Thalji

Greenberg

et al. 2013

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…Antibody-based immunotherapies that activate the complement terminal pathway have been found to be effective in treating some cancers. For example, rituximab is an anticancer immunotherapy that works in part by stimulating the MAC to treat stage III or stage IV follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL). , Unfortunately, some patients are not responsive to rituximab treatment, while others develop resistance over time . Recent data have shown the sensitization of rituximab-resistant B-cell NHL in vitro and in vivo by a CD59 inhibitor derived from ILY. , These findings reinforce the biomedical relevance of understanding complement terminal pathway regulation and how the interplay between MAC and ILY pore formation affects human disease.…”

Section: Medical Implicationsmentioning

confidence: 88%

“…For example, rituximab is an anticancer immunotherapy that works in part by stimulating the MAC to treat stage III or stage IV follicular lymphoma, the most common form of non-Hodgkin's lymphoma (NHL). 77,78 Unfortunately, some patients are not responsive to rituximab treatment, while others develop resistance over time. 79 Recent data have shown the sensitization of rituximab-resistant B-cell NHL in vitro and in vivo by a CD59…”

Section: ■ Medical Implicationsmentioning

confidence: 99%

The Making of a Macromolecular Machine: Assembly of the Membrane Attack Complex

Bubeck

2014

Biochemistry

View full text Add to dashboard Cite

The complement terminal pathway clears pathogens by generating cytotoxic membrane attack complex (MAC) pores on target cells. For more than 40 years, biochemical and cellular assays have been used to characterize the lytic nature of the MAC and to define its protein composition. Although models for pore formation have been inferred from structures of bacterial cytolysins, it was only recently that we were able to visualize how complement components come together during MAC assembly. This review highlights structural analyses of terminal pathway complexes to explore molecular mechanisms underlying MAC formation.

show abstract

“…Health technology assessments for FDA-approved molecular immunotherapies calculated approx. 80,000 euro per quality-adjusted-life-year [ 35 – 39 ]. To this, the costs of managing immune-related adverse effect should be added; approx.…”

Section: Current Issues In Anti-cancer Immunotherapymentioning

confidence: 99%

The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies

et al. 2018

View full text Add to dashboard Cite

This review aims to emphasize the potential of in vivo imaging to optimize current and upcoming anti-cancer immunotherapies: spanning from preclinical to clinical applications. Immunotherapies are an emerging class of treatments for a variety of diseases. The agents include molecular and cellular therapeutics, which aim to treat the disease through re-education of the host immune system, often via complex mechanisms of action. In vivo imaging has the potential to contribute in several different ways: (1) as a drug development tool to improve our understanding of their complex mechanisms of action, (2) as a tool to predict efficacy, for example, to stratify patients into probable responders and likely non-responders, and (3) as a non-invasive treatment response biomarker to guide efficient immunotherapy use and to recognize early signs of potential loss of efficacy or resistance in patients. Areas where in vivo imaging is already successfully implemented in onco-immunology research will be discussed and domains where its use offers great potential will be highlighted. The focus of this article is on anti-cancer immunotherapy as it currently is the most advanced immunotherapy area. However, the described concepts can also be paralleled in other immune-mediated disorders and for conditions requiring immunotherapeutic intervention. Importantly, we introduce a new study group within the European Society of Molecular Imaging with the goal to facilitate and enhance immunotherapy development through the use of in vivo imaging.

show abstract

NICE guidance on rituximab for first-line treatment of symptomatic stage III–IV follicular lymphoma in previously untreated patients

Cited by 4 publications

References 6 publications

Rituximab for Non‐Hodgkin's Lymphoma: A Story of Rapid Success in Translation

Rituximab for Non‐Hodgkin's Lymphoma: A Story of Rapid Success in Translation

The Making of a Macromolecular Machine: Assembly of the Membrane Attack Complex

The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies

Contact Info

Product

Resources

About